Fentanyl Scourge: Nutriband Inc.’s (NASDAQ: NTRB) New Transdermal Patch with Abuse-Deterrent Tech Funded to Seek FDA Approval
150+ Americans die every day from synthetic opioid (e.g. fentanyl) overdose Nutriband’s AVERSA(TM) Fentanyl technology is being developed as an innovative solution to abuse and misuse rates in prescription opioid patch medications Nutriband raised $8.4 million in a private placement to fund AVERSA Fentanyl through FDA Approval Process Fentanyl addiction continues to devastate communities, with current treatment options facing limitations. However, as often happens in healthcare, innovation breeds hope with a new option on the horizon planning to seek FDA marketing approval. The challenges related to the powerful painkiller (up to 50x stronger than heroin and 100x stronger than morphine)…